A CITF-supported study, published in Scientific Reports, aimed to assess the operating characteristics of the International Classification of Diseases Revision 10 (ICD-10) code introduced by the World Health Organization in 2020.
A CITF-funded study, published in BMJ Open, found that universal COVID-19 screening among adults admitted to hospital over two waves in 2020 with a diagnosis unrelated to COVID-19 had a low diagnostic yield, meaning universal screening, at the time, would not have been justifiable as a blanket policy.
The latest CITF-funded report from Canadian Blood Services suggests that seroprevalence due to infection was 82.68% in December 2023, in line with the 82.97% found in November 2023. Consistent with previous reports, the percentage of younger donors (ages 17-24) who had infection-acquired seroprevalence was the highest of all donor age groups.
A research commentary by a CITF-funded researcher published in the Canadian Medical Association Journal discusses how the study populations enrolled in research on oral antivirals (e.g., nirmatrelvir-ritonavir, molnupiravir) are not representative of current COVID-19 patients.
The latest CITF-funded report from Canadian Blood Services suggests that seroprevalence due to infection was 83% in November 2023, up slightly from 81.6% in October 2023. This increase was not statistically significant.
A CITF-funded study, published in BMC Public Health, aimed to obtain a more accurate estimate of the true infection burden of SARS-CoV-2 in the province of Manitoba by accounting for all age groups, vaccination status, and waning antibody levels.
A CITF-funded study, conducted among residents in the Northwest Territories (NWT), found that seroprevalence due to vaccination or infection was greater than 95% in all age groups throughout 2022.
The latest CITF-funded report from Canadian Blood Services suggests that seroprevalence due to infection is now stable among Canadian blood donors at approximately 80%.
The latest CITF-funded report from Canadian Blood Services suggested that seroprevalence due to infection was 80.1% among Canadian blood donors at the end of September 2023. This increased slightly from the 79.0% seroprevalence observed in August 2023.
A CITF-funded study, published in PLos One, found that among patients admitted to hospital who tested positive for SARS-CoV-2 during the Omicron wave, 52% had a primary diagnosis of COVID-19 and the others had incidental SARS-CoV-2 infections.